Cancer early detection firm Grail said after the close of the market Wednesday that its second-quarter revenue grew 26 percent year over year, noting that it is preparing for an expected advisory ...

The technology supports the adoption of digital pathology and artificial intelligence in cancer diagnostics by enabling greater consistency in laboratory slide staining.

The firm also offered updates on its autoimmune disease, newborn screening, and other specialty diagnostics businesses from the sidelines of the conference.

The firm raised its full-year 2026 revenue guidance to a new range of $6.42 billion to $6.48 billion from prior guidance of $6.41 billion to $6.46 billion.

The issue of developing pediatric reference intervals for common laboratory tests has been one of the organization's priorities.

Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

Genprex plans to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies, while Roche will validate assays using its TROP2 antibody.

The ELISA-based CIZ1B Biomarker Blood Test for Lung Cancer is designed to detect the lung cancer-produced biomarker CIZ1B. It was developed by UK-based Cizzle Biotechnology, which licensed it in the ...

This story has been updated to include comments from Labcorp's Q2 2026 earnings call. NEW YORK – Laboratory Corporation of America reported Thursday morning that its second-quarter revenue jumped 6 ...

NEW YORK – Siemens Healthineers on Friday raised its earnings expectations for fiscal 2026 in light of tariff refunds but lowered its overall revenue outlook due in part to declining revenue in the ...

A panel discussion at the Association for Diagnostics & Laboratory Medicine this week tackled questions around coding, reimbursement, and regulation of AI-based tests.